MSB 8.43% $1.35 mesoblast limited

"The study is designed to have three interim analyses for...

  1. 944 Posts.
    lightbulb Created with Sketch. 299
    "The study is designed to have three interim analyses for stopping accrual early for efficacy and futility when 30%, 45% and 60% of the 300 patients have reached the primary endpoint using Bayesian predictive probabilities."

    You had the answer in your post.

    So after 90 patients reach the 30 primary endpoint... all of the 90 patients, not the first of them biggrin.png

    A more likely date is early to mid July.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.